Nicholas Saraceno is Editor of Pharmaceutical Commerce. He can be reached at [email protected].
In the first part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, explains how a federal cap on Medicaid provider taxes could potentially impact hospital systems.
The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient needs through domestic innovation and capacity.
In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts how he anticipates the model growing over the next three to five years, especially as global demand and regulatory complexities increase.
State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.
Access to the GLP-1 will be streamlined, and starting July 1, will result in a limited-time $299 price for eligible self-pay patients.
In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains the lessons pharma leaders in traditional therapeutic areas can learn from CGT’s highly specialized operational strategies, particularly in terms of supply chain resilience and adaptability.
In the second part of this roundtable discussion, a panel of key opinion leaders dive into the key risk factors impacting the pharma manufacturing space, and how the industry should aim to address them.
Dipanwita Das, CEO and co-founder of Sorcero, chats with Pharma Commerce to dig into the evolving drug development landscape, being regulatorily compliant, and the rapid advancements in artificial intelligence.
Analysis compares care quality and efficiency within physician groups that treat Medicare Advantage patients under at-risk contracts, versus fee-for-service.
In the third part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, describes to what extent he believes artificial intelligence should be used at this particular point in time.
The collaborative research initiative will be focused on advancing approaches to enhance the therapeutic efficacy of regulatory T cells and tumor-infiltrating lymphocytes.
In the second part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains how recent shifts in FDA leadership, funding constraints, and evolving CMC standards have each played a role in this process.
When automatically moved from a zero-dollar silver plan to one that requires a premium due to plan turnover, do lower-income health insurance marketplace enrollees lose or switch coverage?
In the first part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, discusses both the successes and challenges in commercializing cell and gene therapies.
The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in biologics.
In the final part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, describes what meaningful drug pricing reform looks like to her.
In the first part of this roundtable discussion, a panel of subject matter experts introduce themselves, while discussing the strategies that are most effective in ensuring resilience across the global supply chain.
The new system meets the increasing demand for faster, more precise processes that enhance quality while boosting efficiency in the pharma manufacturing industry.
A cross-sectional study investigates whether becoming eligible for Medicare at age 65 is linked to changes in healthcare use among individuals experiencing mental health challenges.
In the third part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, explains how a flat admin fee model can potentially create more value for both payers and patients.
Is Medicare plan switching influenced by initial type of Medicare coverage and cancer history?
The 200,000 square-foot Madison, WI facility will serve as the flagship location, with capabilities for future growth.
Stay updated on the Drug Supply Chain Security Act as pharma stakeholders prepare for upcoming deadlines and improved data traceability.
The Asembia AXS25 Summit strives to explore ways to improve patient outcomes, especially for rare and complex diseases.
In the second part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, discusses how this MFN executive order can affect players in the space that operate under a rebate-driven PBM model.
Though this specific agreement centers around aerospace and automobiles, the greater supply chain will wait and see how Trump’s import taxes impact pharmaceuticals, a sector that faces a potential 25% tax on imports.
In the first part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, outlines the most critical root causes of rising healthcare and drug costs that the MFN executive order doesn’t address.
The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city to be named at a later date.
In the third part of her Pharma Commerce video interview, Kirsten Newquist, Identiv’s CEO, shares the ways in which regulations, including DSCSA, are impacting the adoption of smarter packaging technologies across the industry.
In the second part of her Pharma Commerce video interview, Kirsten Newquist, Identiv’s CEO, describes why this technology is essential for pharmaceutical safety and efficacy.
